Featured
Rick Myers discusses Supreme Court ruling on gene patents
News Outlet:
The Huntsville Times, al.com
Date published:
June 17, 2013 
HUNTSVILLE, Alabama - Instead of freezing the market for new genetic products, the U.S. Supreme Court's decision that genes cannot be patented will "bring many more creative minds" to genomic research, the head of the HudsonAlpha Institute for Biotechnology said Monday. Genes cannot be patented now, Dr. Rick Myers said, but new drugs, tests and technologies based on DNA research can be. It will be easier for innovators to generate those new products, Myers said, without having to deal with company patents on the genes needed for their work.
iCell now available on Windows 8 platform
HUNTSVILLE, Ala. – HudsonAlpha’s iCell is now fully available on the Windows 8 platform, potentially reaching an audience of more than 4 million Windows 8 users worldwide. The new Microsoft system features easier-to-open apps for tablets and PCs, making iCell easier to access on Windows 8 devices.
“It simplifies the process of being able to use the iCell application,” said Adam Hott, Ed.D., coordinator of educational outreach. “This makes iCell more accessible and puts it in the hands of users more efficiently.”
Jeremy Schmutz receives cotton biotechnology award
News Outlet:
PR Newswire
Date published:
January 16, 2013
HUNTSVILLE, Ala. -- iCell, the interactive app created by the HudsonAlpha Institute for Biotechnology to help students visualize the inside of a typical cell, has just passed 250,000 downloads on iTunes. It's the latest accomplishment for a free app that's making news in the educational world. iCell is also available through the Android and Windows stores and can be viewed at
HudsonAlpha's educational outreach team received a big boost from BBVA Compass Bank when the local financial institution donated almost $6,000 toward the Science for Me Too! program.
HUNTSVILLE, Ala. -- EGEN, Inc. today announced that it has recently initiated a Phase I clinical trial of its novel immunotherapy agent, EGEN-001, in combination with PEGylated liposomal Doxorubicin or Lipodox for the treatment of recurrent ovarian cancer. The EGEN-sponsored trial is conducted by a network of researchers led by Gynecologic Oncology Group (GOG) at member institutions under an agreement between the GOG and EGEN, Inc. Premal Thaker, M.D., M.S., of Washington University School of Medicine, is the Study Chair for the trial.
Huntsville, Ala. – Joseph M. Cosumano joins CFD Research Corporation (CFDRC) as president, effective Feb. 1, 2013. Cosumano’s military and civilian experience in key modernization efforts make him a perfect fit to lead CFDRC as it continues to make significant discoveries and applications.
Serina Therapeutics, Inc. has developed a proprietary, patented polymer technology for drug development and announced an agreement with AstraZeneca to develop the polyoxazoline (POZ) polymer therapeutic with an AstraZeneca proprietary compound. The nature of the POZ therapeutic and the terms of the agreement were not immediately disclosed.